---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-140148"
form_type: "8-K"
ticker: "NERV"
cik: "0001598646"
company_name: "Minerva Neurosciences, Inc."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:50:39.426013+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Minerva Neurosciences President resigns; James O'Connor named Chief Business Officer and General Counsel

## Summary
- Geoffrey Race resigned as President effective March 31, 2026 after 16 years with the company.
- Race will serve as consultant from April 15, 2026 to April 14, 2027 at £333/hour (min 35 hrs/month).
- James O'Connor appointed Chief Business Officer and General Counsel effective April 21, 2026.
- Press release highlights focus on roluperidone for negative symptoms of schizophrenia and planned Phase 3 trial.
- Race receives full vesting of outstanding stock options with exercise period extended to January 1, 2030.

## SEC filing metadata
- accession: 0001193125-26-140148
- form_type: 8-K
- ticker: NERV
- cik: 0001598646
- company_name: Minerva Neurosciences, Inc.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1598646/000119312526140148/0001193125-26-140148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1598646/000119312526140148/d143634d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-140148
- JSON: https://secwatch.observer/filing/0001193125-26-140148.json
- Plain text: https://secwatch.observer/filing/0001193125-26-140148.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.